Enzyme replacement therapy in late-onset Pompe disease: A systematic literature review

Antonio Toscano, Benedikt Schoser

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Glycogen storage disease type 2/Pompe disease is a progressive muscle disorder with a wide range of phenotypic presentations, caused by an inherited deficiency of acid alpha-glucosidase. Since 2004 only a limited number of patients have been treated with recombinant human alpha-glucosidase from rabbit milk whereas since 2006 enzyme replacement therapy (ERT) with alglucosidase alfa has been licensed for the treatment of Pompe disease. This systematic review evaluates the clinical efficacy and safety of alglucosidase alfa treatment of juvenile and adult patients with late-onset Pompe disease (LOPD). Studies of alglucosidase alfa treatment of LOPD patients - published up to January 2012 - were identified by electronic searching of the EMBASE and MEDLINE databases, and manual searching of the reference lists. Data on ERT outcomes were extracted from selected papers and analyzed descriptively. No statistical analysis was performed owing to data heterogeneity. Twenty-one studies containing clinical data from 368 LOPD patients were analyzed. Overall, at least two-thirds of patients were stabilized or had improved creatine kinase levels and muscular and/or respiratory function following treatment with alglucosidase alfa. ERT was well tolerated; most adverse events were mild or moderate infusion-related reactions. In conclusion, alglucosidase alfa treatment is effective and well tolerated and attenuates progression of LOPD in most patients. Further research is required to investigate factors such as age at diagnosis, phenotypic presentation, and genotypic characteristics, identification of which may enable better clinical and therapeutic management of LOPD patients.

Original languageEnglish
Pages (from-to)951-959
Number of pages9
JournalJournal of Neurology
Volume260
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Glycogen Storage Disease Type II
Enzyme Replacement Therapy
Therapeutics
Late Onset Disorders
alpha-Glucosidases
Muscular Diseases
Creatine Kinase
MEDLINE
Milk
human GAA protein
Databases
Rabbits
Safety

Keywords

  • Alglucosidase alfa
  • Enzyme replacement therapy
  • Glycogen storage disease type 2
  • Late-onset Pompe disease (LOPD)
  • Systematic review

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Enzyme replacement therapy in late-onset Pompe disease : A systematic literature review. / Toscano, Antonio; Schoser, Benedikt.

In: Journal of Neurology, Vol. 260, No. 4, 04.2013, p. 951-959.

Research output: Contribution to journalArticle

Toscano, Antonio ; Schoser, Benedikt. / Enzyme replacement therapy in late-onset Pompe disease : A systematic literature review. In: Journal of Neurology. 2013 ; Vol. 260, No. 4. pp. 951-959.
@article{2e808fe37738462cb28a556199464250,
title = "Enzyme replacement therapy in late-onset Pompe disease: A systematic literature review",
abstract = "Glycogen storage disease type 2/Pompe disease is a progressive muscle disorder with a wide range of phenotypic presentations, caused by an inherited deficiency of acid alpha-glucosidase. Since 2004 only a limited number of patients have been treated with recombinant human alpha-glucosidase from rabbit milk whereas since 2006 enzyme replacement therapy (ERT) with alglucosidase alfa has been licensed for the treatment of Pompe disease. This systematic review evaluates the clinical efficacy and safety of alglucosidase alfa treatment of juvenile and adult patients with late-onset Pompe disease (LOPD). Studies of alglucosidase alfa treatment of LOPD patients - published up to January 2012 - were identified by electronic searching of the EMBASE and MEDLINE databases, and manual searching of the reference lists. Data on ERT outcomes were extracted from selected papers and analyzed descriptively. No statistical analysis was performed owing to data heterogeneity. Twenty-one studies containing clinical data from 368 LOPD patients were analyzed. Overall, at least two-thirds of patients were stabilized or had improved creatine kinase levels and muscular and/or respiratory function following treatment with alglucosidase alfa. ERT was well tolerated; most adverse events were mild or moderate infusion-related reactions. In conclusion, alglucosidase alfa treatment is effective and well tolerated and attenuates progression of LOPD in most patients. Further research is required to investigate factors such as age at diagnosis, phenotypic presentation, and genotypic characteristics, identification of which may enable better clinical and therapeutic management of LOPD patients.",
keywords = "Alglucosidase alfa, Enzyme replacement therapy, Glycogen storage disease type 2, Late-onset Pompe disease (LOPD), Systematic review",
author = "Antonio Toscano and Benedikt Schoser",
year = "2013",
month = "4",
doi = "10.1007/s00415-012-6636-x",
language = "English",
volume = "260",
pages = "951--959",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "4",

}

TY - JOUR

T1 - Enzyme replacement therapy in late-onset Pompe disease

T2 - A systematic literature review

AU - Toscano, Antonio

AU - Schoser, Benedikt

PY - 2013/4

Y1 - 2013/4

N2 - Glycogen storage disease type 2/Pompe disease is a progressive muscle disorder with a wide range of phenotypic presentations, caused by an inherited deficiency of acid alpha-glucosidase. Since 2004 only a limited number of patients have been treated with recombinant human alpha-glucosidase from rabbit milk whereas since 2006 enzyme replacement therapy (ERT) with alglucosidase alfa has been licensed for the treatment of Pompe disease. This systematic review evaluates the clinical efficacy and safety of alglucosidase alfa treatment of juvenile and adult patients with late-onset Pompe disease (LOPD). Studies of alglucosidase alfa treatment of LOPD patients - published up to January 2012 - were identified by electronic searching of the EMBASE and MEDLINE databases, and manual searching of the reference lists. Data on ERT outcomes were extracted from selected papers and analyzed descriptively. No statistical analysis was performed owing to data heterogeneity. Twenty-one studies containing clinical data from 368 LOPD patients were analyzed. Overall, at least two-thirds of patients were stabilized or had improved creatine kinase levels and muscular and/or respiratory function following treatment with alglucosidase alfa. ERT was well tolerated; most adverse events were mild or moderate infusion-related reactions. In conclusion, alglucosidase alfa treatment is effective and well tolerated and attenuates progression of LOPD in most patients. Further research is required to investigate factors such as age at diagnosis, phenotypic presentation, and genotypic characteristics, identification of which may enable better clinical and therapeutic management of LOPD patients.

AB - Glycogen storage disease type 2/Pompe disease is a progressive muscle disorder with a wide range of phenotypic presentations, caused by an inherited deficiency of acid alpha-glucosidase. Since 2004 only a limited number of patients have been treated with recombinant human alpha-glucosidase from rabbit milk whereas since 2006 enzyme replacement therapy (ERT) with alglucosidase alfa has been licensed for the treatment of Pompe disease. This systematic review evaluates the clinical efficacy and safety of alglucosidase alfa treatment of juvenile and adult patients with late-onset Pompe disease (LOPD). Studies of alglucosidase alfa treatment of LOPD patients - published up to January 2012 - were identified by electronic searching of the EMBASE and MEDLINE databases, and manual searching of the reference lists. Data on ERT outcomes were extracted from selected papers and analyzed descriptively. No statistical analysis was performed owing to data heterogeneity. Twenty-one studies containing clinical data from 368 LOPD patients were analyzed. Overall, at least two-thirds of patients were stabilized or had improved creatine kinase levels and muscular and/or respiratory function following treatment with alglucosidase alfa. ERT was well tolerated; most adverse events were mild or moderate infusion-related reactions. In conclusion, alglucosidase alfa treatment is effective and well tolerated and attenuates progression of LOPD in most patients. Further research is required to investigate factors such as age at diagnosis, phenotypic presentation, and genotypic characteristics, identification of which may enable better clinical and therapeutic management of LOPD patients.

KW - Alglucosidase alfa

KW - Enzyme replacement therapy

KW - Glycogen storage disease type 2

KW - Late-onset Pompe disease (LOPD)

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84876476681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876476681&partnerID=8YFLogxK

U2 - 10.1007/s00415-012-6636-x

DO - 10.1007/s00415-012-6636-x

M3 - Article

C2 - 22926164

AN - SCOPUS:84876476681

VL - 260

SP - 951

EP - 959

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 4

ER -